Comprehensive real-time dashboard tracking breakthrough dengue vaccine development. Monitor WHO-approved Qdenga and Dengvaxia, revolutionary single-dose Butantan-DV, and emerging candidates across 4 DENV serotypes.
Prequalified dengue vaccines: Qdenga (TAK-003) and Dengvaxia (CYD-TDV) for use in endemic countries
Large-scale efficacy trials with thousands of participants in endemic regions
Expanded safety, immunogenicity, and preliminary efficacy assessment
First-in-human safety testing and dose-finding in healthy volunteers